Recent developments in human papillomavirus diagnosis and therapy in genital neoplasia

Bibliography

• WALBOOMERS JMM, JACOBS MV, MANOS MM et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Path. (1999) 189:12–19.
   PubMed Web of Science ®Google Scholar
• •Key study establishing ubiquity of HPV assocciation with cervical cancer.
   Google Scholar
• NOBBENHUIS MAE, WALBOOMERS, HELMERHORST TJM et al.: Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet (1999) 354:20–25.
   PubMed Web of Science ®Google Scholar
• •Shows persistant high risk HPV is a major risk for progression.
   Google Scholar
• ZUR HAUSEN H: Papillomavirus infections- a major cause of human cancers. Biochim. Biophy. Acta (1996) 1288:F55–78.
   PubMed Web of Science ®Google Scholar
• CHOW LT, BROKER TR: Small DNA tumor viruses. In: Vim/Pathogenesis. Nathanson N, Ahmed R, Gonzalez-Scarano F et al (Eds.), Lippincott-Raven, Philadelphia, USA (1997):267–301.
   Google Scholar
• LIU JS, KUO SR, BROKER TR, CHOW LT: The functions of human papillomavirus Type 11 El, E2 and E2c proteins in cell-free DNA replication. j Biol. Chem. (1995) 270:27283–27291.
   PubMed Web of Science ®Google Scholar
• DOORBAR J, FOO C, COLEMAN Netal.: Characterisation of events during the late stages of HPV 16 infection in vivo using high affinity synthetic Fabs to E4. Virology (1997) 238:40–52.
   Google Scholar
• CROOK T, VOUSDEN KH: HPV oncoprotein function. In: Papillomavrius: Current Research on. Lacey C (Ed.), Leeds University Press, Leeds, UK (1996):55–60.
   Google Scholar
• KOROMILAS AE, LI S, G: Control of interferon signalling in human papillomavirus infection. Cytokirie Growth Factor Rev (2001) 65:157–170.
   Google Scholar
• ••Wide ranging review of HPV E6/E7influences on interferon and related pathways.
   Google Scholar
• CULLEN AP REID R, CAMPION M, LORINCZ AT: Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J. Viral (1991) 65:606–612.
   PubMed Web of Science ®Google Scholar
• RADER JS, KAMARASOVA T, HUETTNER PC, LI L, LI Y, GERHARD DS: Allelotyping of all chromosomal markers in invasive cervical cancer. Oricogerie 1996) 13:2737–2741.
   Google Scholar
• JACOBS MV, WALBOOMERS JMM, SNIJDERS PJF, VOORHORST FJ, FRANSEN-DAALMEIJER N, MEIJER CJLM: Age-related distribution patterns of 37 mucosotropic HPV types in women with cytomorphologically normal cervical smears: decreased highilow risk ratio at older age. Int. I Cancer (2000) 87:221–227.
   PubMed Web of Science ®Google Scholar
• OZSARAN AA, ATES T, DIKMEN Y etal.: Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur. I Gyrraecol. Orical. (1999) 20:127–30.
   Google Scholar
• VAN OORTMARSSEN GJ, HABBEMA JDF, VAN BALLEGOOIJEN M: Predicting mortality from cervical cancer after negative smear results. Br Med. (1992) 305:449–451.
   PubMed Web of Science ®Google Scholar
• SANTOS C, MUNOZ N, KLUG S etal.:HPV types and cofactors causing cervical cancer in Peru. Br .j Cancer (2001) 85:966–971.
   Google Scholar
• GRAVITT PE, PEYTON CL, ALESSI TQet al.: Improved amplification of genital human papillomavirus. j OM. Microbial. (2000) 38:357–361.
   Google Scholar
• JACOBS MV, VAN DEN BRULE AJC, SNIJDERS PJF, MEIJER CJLM, HELMERHORST THJM, WALBOOMERS JMM: A general primer GP546+ mediated PCR-EIA for rapid detection of high- and low-risk HPV DNA in cervical scrapes. j OM. 11/licrobial. (1997) 35:791–795.
   Google Scholar
• VAN DEN BRULE AJC, POL R, FRANSEN-DAALMEIJER N, SCHOULS LM, MEIJER CJLM, SNIJDERS PJF: GP546+ PCR followed by Reverse Line Blot analysis enables rapid and high throughput identification of HPV genotypes, suitable for mass screening. Clin. Microbial. (2001) (In press).
   Google Scholar
• PEYTON CL, SCHIFFMAN M, LORINCZ AT et al. Comparison of PCR-and Hybrid Capture-Based Human Papillomavirus Detection Systems using multiple cervical specimen collection strategies. I OM. 11/licrobial. (1998) 36:3248–3254.
   Google Scholar
• SASIENI PD, ADAMS J: Analysis of cervical cancer mortality and incidence data from England and Wales: evidence of a beneficial effect of screening. I R. Stat. Soc. Series A (2000) 163:191–209.
   Web of Science ®Google Scholar
• •Screening saves lives.
   Google Scholar
• CUZICK J, SASIENI P, DAVIES P et al.: A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol. Assess. (1999) 3:1–96.
   Google Scholar
• MANOS M, KINNEY WK, HURLEY LB et al.: Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA (1999) 281:1605–610.
   PubMed Web of Science ®Google Scholar
• JOSEFSSON AM, MAGNUSSON PK, YLITALO N etal.: Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet (2000) 355:2189–2193.
   Google Scholar
• •An example of the use of realtime PCR for measuring viral load.
   Google Scholar
• KLAES R, WOERNER SM, RIDDER R et.: Detection of high risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. (1999) 59:6132–6136.
   Google Scholar
• •An important method for determining HPV integration status.
   Google Scholar
• LUFT F, KLAES R, NEES M et al.: of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterisation in cervical cancer cells. mt. j Cancer (2001) 92:9–17.
   PubMed Web of Science ®Google Scholar
• ZIEGERT C, VINOKOUROVAL S, KISSELJOV F, VON KNEIBEL DOBERITZ M, NINDL I: HPV 16 and HPV 18 genome integration in invasive cancer-a clonal event? 19th Human Papillomavirus Conference Florarropolis, Brazil (2001).
   Google Scholar
• NEES M, GEOGHEGAN JM, HYMAN T, FRANKS, MILLER L, WOODWORTH CD: Papillomavirus Type 16 oncognes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-1(3-responsive genes in cervical keratinocytes. I Viral. (2001) 75:4283–4296.
   Google Scholar
• ••Microarray gene screen for consequencesof HPV 16 E6 or E7 expression.
   Google Scholar
• PARK JS, KIM EJ, KWON HJ, SE, UM SJ: Inactivation of interferon regulatory factor-I tumour suppressor protein by HPV E7 oncoprotein. Implication for E7-mediated immune evasion mechanisms in cervical carcinogenesis. I Biol. Chem. (2000) 275:6764–6769.
   Google Scholar
• CHANG YE, LAIMINS LA: Microarray analysis identifies interferon inducible genes and Stat-1 as major transcriptional targets of human papillomavirus Type 31.1 Viral. (2000) 74:4174–4182.
   PubMed Web of Science ®Google Scholar
• BARNARD P, McMILLAN NAJ: The human papillomavirus E7 oncoprotein abrogates signalling mediated by interferon-a. Virology(1999) 259:305–313.
   PubMed Web of Science ®Google Scholar
• LI S, LEBREQUE S, GAUZZI MC et al.: The human papillomavirus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-a. Oricagerre (1999) 18:5727–5737.
   Google Scholar
• SWAIN SL: Interleukin 18: Tipping the balance towards a T helper cell 1 response. Exp. Med.(2001) 194:F11–14.
   Web of Science ®Google Scholar
• CHO Y-S, KANG J-W, CHO M et al.: Down modulation of IL-18 expression by human papillomavirus Type 16 E6 oncogene via binding to IL-18. FEBS Lett. (2001) 501:139–145.
   PubMed Web of Science ®Google Scholar
• ••HPV immune evasion strategy.
   Google Scholar
• KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLER JT: Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Nati Acad. Sri. USA (1992) 89:12180–12184.
   PubMed Web of Science ®Google Scholar
• SCHILLER JT, LOWY DR: Papillomavirus-like particles vaccines. Natl. Cancer Inst. Monogr. (2001) 28:50–54.
   Google Scholar
• •Recent review of VIP vaccine approaches.
   Google Scholar
• SCHILLER JT, HIDESHEIM A: Developing HPV virus-lik e particles to prevent cervical cancer: a progress report. OM. Viral. (200) 19:67–74.
   Google Scholar
• STERN PL, FAULKNER RF, VERANES EC, DAVIDSON EJ: HPV vaccines in cervical neoplasia In: Best Practice & Research volume 15(5). Clinical Obstetrics & Gynaecology Kitchener HC (Ed.), Bailliere Tindall, London, UK (2000:783–799.
   Google Scholar
• ••Recent review of vaccines (Volume 15contains comprehensive reviews covering all aspects of cervical neoplasia).
   Google Scholar
• GOUGH G: Human papillomavirus: recent devlopments in diagnosis and therapy. Expert Opin. Ther. Patents (1997) 7:821–828.
   Web of Science ®Google Scholar
• HARRO CD, PANG Y-YS, RODEN RBS etal.: Safety and immunogencity trial in adult volunteers of a human papillomavirus 16 Li virus-like particle vaccine. I Nati Cancer Inst. (2001) 93:284–292.
   Google Scholar
• •First results of a VLP trial.
   Google Scholar
• RODEN R, YUTZY WH, FALLON R, INGLIS S, LOWY DR, SCHILLER JT: Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralising epitopes. Virology (2000) 270:254–257.
   PubMed Web of Science ®Google Scholar
• GIROGLOU T, FLORIN L, SCHAFER E STREEK RE, SAPP M: Human papillomavirus infection requires cell surface heparan sulfate. j. Viral. (2001) 75:1565–1570.
   PubMed Web of Science ®Google Scholar
• JOYCE JG, TUNG J-S, PRZYSIECKI CT et al.: The Li major capsid protein of human papillomavirus typell recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. I Biol. Chem. (1999) 274:5810–5822.
   Web of Science ®Google Scholar
• DA SILVA DM,VELDERS MP, NIELAND JD, SCHILLER JT, NICKOLOFF BJ, KAST WM: Physical interaction of human papillomavirus virus-like particles with immune cells. Int. ImmurraL 113: 633–641.
   Google Scholar
• MULLER M, ZHOU J, REED TD et al.: Chimeric papillomavirus-like particles. Virology (1997) 234:93–111.
   PubMed Web of Science ®Google Scholar
• GREENSTONE HL, NIELAND JD, VISSER KE et al.: Chimeric papillomavirus-like particles elicit antitumour immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc. Natl. Acad. Sci. USA (1998) 95:1800–1805.
   PubMed Web of Science ®Google Scholar
• ••Chimeric VLP can induce CTL.
   Google Scholar
• SCHAFER K, MULLER M, FAATH S et al.: Immune responses to human papillomavirus-like particles: induction of cytotoxic T cells and specific tumor protection. Int. J. Cancer (1999) 81:121–128.
   Web of Science ®Google Scholar
• LENZ E DAY PM, PANG YY et al.: Papillomavirus-like particles induce acute activation of dendritic cells. j. ImmurraL (2001) 166:5361–5355.
   Google Scholar
• RUDOLF MP, FAUSCH SC, DA SILVA DM, KAST WM.: Human dendritic cells are activated by chimeric human papillomavirus Type 16 virus-like particles and induce epitope-specific human T cell responses in vitro. I hnmurraL (2001) 166:5917–5924.
   Google Scholar
• KAUFMAN AM, NIELAND J, SCHINZ et al.: HPV 16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. J. Cancer (2001) 92:285–293.
   Web of Science ®Google Scholar
• ADAMS M, JASENI B, COLACO CALS, MASON MD: Dendritic cell approaches to immunotherapy. In: Cancer Vaccines and Immunotherapy Stern PL, Beverley PLC, Carroll MW (Eds.), Cambridge University Press, Cambridge, UK (2000):237–255.
   Google Scholar
• RESSING ME, VAN DRIEL WJ, BRANDT RIVI et al.: Detection of T helper response, but not of human papillomavirus Type 16 specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. j. Immunother. (2000) 23:255–266.
   PubMed Web of Science ®Google Scholar
• MUDERSPACH L, WILCYNSKI S, ROMAN L et al.: A Phase 1 trial of a human papillomavirus (HPV) peptide vaccine for women with high grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. (2000) 6: 3406–3416.
   PubMed Web of Science ®Google Scholar
• JI H, WANG TL, CHEN CH et al.: Targeting human papillomavirus Type 16 E7 to the endosomalhysosomal compartment enhances the antitumor activity of DNA vaccines against murine human papillomavirus Type 16 El-expressing tumors. Hum. Gene Ther. (1999) 10:2727–2740.
   PubMed Web of Science ®Google Scholar
• MASCHER B. SCHLENKE P, M: Expression and kinetics of cytokines dtermined by intracellular staining using flow cytometry. I ImmurraL Methods (1999) 223:1115–1121.
   Web of Science ®Google Scholar
• MCMICHAEL AJ, O'CALLAGHAN CA: A new look at T cells. I Exp. Med. (1998) 187:1367–1371.
   PubMed Web of Science ®Google Scholar
• YOUDE SJ, DUNBAR PR, EVANS EM et al.: Use of fluorogenic histocompatibility leukocyte antigen-A*0201 HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocytes recognizing endogeneous human papillomavirus antigens. Cancer Res. (2000) 60:365–371.
   PubMed Web of Science ®Google Scholar
• HOHN H, PILCH H, GUNZEL S et al.:CD4+ tumour-infiltrating lymphocytes in cervical cancer HLA-DR-restricted peptides provide by human papillomavirus ImmurraL (1999) 163:5715–5722.
   Google Scholar
• VAN DER BURG SH, RESSING ME, KWAPPENBERG KIVIC etal.: Natural T-helper immunity against human papillomavirus Type 16 (HPV 16) E7-derived peptide epitopes in patients with HPV-16 positive cervical lesions: identification of 3 human leukocyte antigen II-restricted epitopes. bit. j. Cancer (2001) 91:612–618.
   Google Scholar
• DE GRUIJL TD, BONTKES HJ, WALBOOMERS JM et al.: Differential T cell cell responses to human papillomavirus E7 reeked to viral clearance or persistence in patients with cervical neoplasia: a longditudinal study. Cancer Res. (1998) 58:1700–1706.
   PubMed Web of Science ®Google Scholar
• AL-SALEH W, GIANNINI SL, JACOBS N et al.: Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix. j. PathaL (1998) 184:283–290.
   PubMed Web of Science ®Google Scholar
• SCOTT M, STITES DP, MOSCICKI AB: Thl cytokine patterns in cervical papillomavirus infection. Clin. Diagn Lab. Immune]. (1999) 6:751–755.
   PubMedGoogle Scholar
• CHU NR, WU HB, WU T, BOUX LJ, SIEGEL MI, MIZZEN LA: Immunotherapy of a human papillomavirus (HPV) Type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immune]. (2000) 121:216–225.
   PubMed Web of Science ®Google Scholar
• ••Heat shock-HPV oncogene fusion asvaccines.
   Google Scholar
• DIEHL L, DEN BOER AT, VAN DER VOORT El, MELIEF CJ, OFFRINGA R, TOES RE: The role of CD40 in peripheral T cell tolerance and immunity. Mal. Med. (2000) 78:363–367.
   PubMed Web of Science ®Google Scholar
• SCHOELL WMJ, MIRHASHEMI R, LIU B et al.: Generation of tumour specific cytotoxic T lymphocytes by stimulation with HPV Type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer. Cyr]. OricaL (1999) 74:448–455.
   Google Scholar
• SANTIN AD, HERMONAT PL, RAVAGGI A et al.: Induction of human papillomavirus-specific CD4+ and CD8+ lymphocytes by El-pulsed autologous dendritic cells in patients with human papillomavirus Type 16- and 18-positive cervical cancer. j. Viral. (1999) 73:5402–5410.
   PubMed Web of Science ®Google Scholar
• SANTIN AD, HERMONAT PL, RAVAGGI A et al.: Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7-pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. Eur.. Oiled. (2000) 21:17–23.
   Google Scholar
• GARRIDO F, RUIZ-CABELLO E CABRERA T etal.: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immortal. Today (1997) 18:89–95.
   Google Scholar
• BONTKES HJ, WALBOOMERS JM, MEIJER CJ, HELMERHORST TJ, STERN PL: Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet (1998) 351:187–188.
   PubMed Web of Science ®Google Scholar
• VAN EN BURG SH, KWAPPENBERG KM, O'NEILL T et al.: Preclinical safety and efficacy of TA-CIN, a recombinant HPV 16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine (2001) 19:3652–3660.
   Google Scholar
• •Prime-boost study in HPV predinical model.
   Google Scholar
• REVAZ V, BENYACUB J, KAST WM et al.: Mucosal vaccination with a recombinant Salmonella nphimurium expressing human papillomavirus Type 16 (HPV16) Li virus-like particles (VLPs) or HPV16VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology (2001) 279:354–360.
   PubMed Web of Science ®Google Scholar